A single-arm, observational, prospective cohort study of dupilumab on patient-reported outcomes and symptoms in asthma
Latest Information Update: 24 Dec 2021
Price :
$35 *
At a glance
- Drugs Dupilumab (Primary)
- Indications Asthma
- Focus Therapeutic Use
- Acronyms RESPIRE
- 24 Dec 2021 New trial record